Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TG Celebrates High Risk CLL Data - But Cloud Looms From Rival Trial

Executive Summary

TG Therapeutics is savoring positive trial data on its investigational TG-1101 in high risk CCL - but that could be soured next year by a little known mid-stage trial of Imbruvica plus Rituxan.

Advertisement

Related Content

J.P. Morgan Notebook Day 4: CRISPR's Not Worried; Theratechnologies' HIV Niche; And Is Moderna's IPO Coming Soon?
J.P. Morgan Notebook Day 4: CRISPR's Not Worried; Theratechnologies' HIV Niche; And Is Moderna's IPO Coming Soon?
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
Finance Watch: Two New VC Funds Raise $500m; One New US IPO; And Galena's 'Strategic Review'

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098363

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel